Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.52 USD | -21.43% | -13.51% | +137.84% |
05-02 | Transcript : Cardiff Oncology, Inc., Q1 2024 Earnings Call, May 02, 2024 | |
05-02 | Cardiff Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Novel Therapies for Cancers
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | +26.42% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | +26.42% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Mark Erlander
CEO | Chief Executive Officer | 64 | 03/03/13 |
James Levine
DFI | Director of Finance/CFO | 53 | 11/07/21 |
Tod Smeal
CTO | Chief Tech/Sci/R&D Officer | 59 | 10/01/22 |
Chief Tech/Sci/R&D Officer | - | 30/01/23 | |
Vicki Kelemen
COO | Chief Operating Officer | - | 31/12/14 |
Charles Monahan
LAW | General Counsel | - | 10/01/22 |
Brigitte Lindsay
PRN | Corporate Officer/Principal | - | 31/12/11 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
James Armitage
BRD | Director/Board Member | 77 | 21/04/20 |
Gary Pace
BRD | Director/Board Member | 76 | 21/04/20 |
Mark Erlander
CEO | Chief Executive Officer | 64 | 03/03/13 |
Lâle White
BRD | Director/Board Member | 68 | 21/04/20 |
Mani Mohindru
BRD | Director/Board Member | 52 | 09/06/21 |
Rodney Markin
CHM | Chairman | 67 | 18/02/14 |
Renee Tannenbaum
BRD | Director/Board Member | 72 | 09/06/21 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 44,710,391 | 41,334,236 ( 92.45 %) | 0 | 92.32 % |
Stock B | 0 | 61,000 | 0 | 0 |
Company contact information
Cardiff Oncology, Inc.
11055 Flintkote Avenue
92121, San Diego
+858 952 7570
http://www.cardiffoncology.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+137.84% | 157M | |
+25.69% | 47.86B | |
+46.90% | 41.42B | |
-3.46% | 40.66B | |
-6.20% | 28.92B | |
+9.17% | 25.55B | |
-20.42% | 19.27B | |
+0.17% | 12.15B | |
+28.07% | 12.14B | |
-1.24% | 11.99B |
- Stock Market
- Equities
- CRDF Stock
- Company Cardiff Oncology, Inc.